Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

BACKGROUND: There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and several neuropsychiatric disorders, but results of the majority of oxytocin random...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Alzheimers Res Ther
Auteurs principaux: Finger, Elizabeth, Berry, Scott, Cummings, Jeffrey, Coleman, Kristy, Hsiung, Robin, Feldman, Howard H., Boxer, Adam
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161323/
https://ncbi.nlm.nih.gov/pubmed/30261917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-018-0427-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires